College of Medicine, Qatar University, Doha, Qatar.
Bosn J Basic Med Sci. 2019 Aug 20;19(3):227-233. doi: 10.17305/bjbms.2019.4204.
The treatment of several solid and hematologic malignancies with immune checkpoint inhibitors (against programmed death receptor-1/ligand-1 [PD-1/PD-L1]) has dramatically changed the cancer treatment paradigm. However, no checkpoint inhibitors were previously approved for the treatment of triple-negative breast cancer (TNBC), a difficult-to-treat disease with a high unmet therapeutic need. Based on IMpassion130 clinical trial (NCT02425891), the Food and Drug Administration (FDA) has recently granted an accelerated approval for atezolizumab (TECENTRIQ®), a monoclonal antibody drug targeting PD-L1, plus chemotherapy (Abraxane; nab®-Paclitaxel) for the treatment of adults with PD-L1-positive, unresectable, locally advanced or metastatic TNBC. The FDA has also approved the Ventana diagnostic antibody SP142 as a companion test for selecting TNBC patients for treatment with atezolizumab. In the present review, we briefly discuss the importance of this breakthrough as the first cancer immunotherapy regimen to be approved for the management of breast cancer.
免疫检查点抑制剂（针对程序性死亡受体 1/配体 1 [PD-1/PD-L1]）治疗几种实体瘤和血液系统恶性肿瘤，极大地改变了癌症治疗模式。然而，以前没有检查点抑制剂被批准用于治疗三阴性乳腺癌（TNBC），这是一种难以治疗的疾病，治疗需求未得到满足。基于 IMpassion130 临床试验（NCT02425891），美国食品药品监督管理局（FDA）最近加速批准了针对 PD-L1 的单克隆抗体药物阿替利珠单抗（TECENTRIQ®），联合化疗（Abraxane；nab®-紫杉醇），用于治疗 PD-L1 阳性、不可切除、局部晚期或转移性 TNBC 的成人患者。FDA 还批准了 Ventana 诊断抗体 SP142 作为选择 TNBC 患者接受阿替利珠单抗治疗的伴随检测。在本综述中，我们简要讨论了这一突破的重要性，这是第一个被批准用于乳腺癌治疗的癌症免疫治疗方案。
